Factor in Biological Technology

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with he...

AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities

Masimo also receives the AARC Zenith Award for Equipment and Service Excellence at the 54th Annual International Respiratory Congress in Anaheim IRVINE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and Measure-Through-Motion and Low...

deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service

REYKJAVIK, Iceland, Dec. 8 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated wi...

Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that data related to the Company's series of novel comp...

Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that it has begun patient enrollment in a large Phase ...

New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture

Leading researchers in academia and industry reveal powerful effects of recombinant lactoferrin (tradename: Lacromin) in mammalian cell culture leading to a significant boost in productivity. FORT COLLINS, Colo., Oct. 10 /PRNewswire/ -- A recently published study in the scientific...

China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII

TAIAN CITY, Shandong, China, Sept. 17 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that the Comp...

Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) today announced that it has out-licensed all worldwide rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes the clinical drug candidate Avrina(TM), to Transcription Factor Therapeutics,...

New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor

SEATTLE, May 1 /PRNewswire/ -- Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results, especially if a major tumor suppressor gene -- p53 -- is already compromised, accor...

Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods

RESEARCH TRIANGLE PARK, N.C., Feb. 25 /PRNewswire/ -- Attagene Inc., a biotechnology company that develops innovative tools for signal transduction analysis, announced today that one of the Nature Research Journals highlights their flagmanship technology, the FACTORIAL(TM). In advance online p...

Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding

BOTHELL, Wash., Dec. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK ) announced today that they have entered into a feasibility study with an undisclosed global leader in the production of plasma products, to develop an alternative dosage form of Factor IX prote...

Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and Other Cancers

Potential to halt cancer cell growth without interfering with insulin may address limitations of current IGF inhibitors SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a wholly-owned subsidiary of...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

Huge Opportunity Exists for Development of More Effective Therapies That Can Improve Survival, According to a New Report from Decision Resources WALTHAM, Mass., Sept. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthca...

Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway

SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), today announced they have entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) of...

Aldrichimica Acta Ranked First in Organic Chemistry by Impact Factor

Sigma-Aldrich continues to make the Acta more useful and accessible to scientists around the world ST. LOUIS, July 15 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) is proud to announce that its highly acclaimed chemistry review journal, Aldrichimica Acta, has aga...

Lowering the fear factor for entrepreneurs, intra-preneurs

MILWAUKEE,WI.-Beware calling the next strange idea you hear strange: the person touting it just might be the next millionaire next door. A panel of experienced entrepreneurs speaking to attendees at the first Wisconsin Entrepreneurs Conference in Milwaukee last Wednesday have dealt with looks a...

Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor

Sylviane Komesli, Martine Page, and Patrick Dutartre Dpartement dImmunologie, Laboratoires Fournier S.A., France Abstract TGF- type I and type II receptors form ligand dependent heteromeric signaling complexes, in which transforming growth fact...

Is Z' factor the best assessment for the quality of cellular assays delivering higher content?

Elizabeth P. Roquemore, Sam Murphy, *Stephen J. Capper, Suzanne M. Hancock, Elaine Adie, Molly Price-Jones, Stephen Game & Stuart Swinburne Amersham Biosciences UK Limited, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA England ...

Your Data: Silencing of a Pro-apoptotic Transcription Factor Using Synthetic siRNA

One of the RNA silencing products available from Ambion is a kit for the synthesis of siRNA, the Silencer factor Receptor (VEGFR) inhibitors." However, chemotherapy continues to be used widely for now. This may be attributed to the fact that the use of tar...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...n is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and bot...cal programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in a multi-center, controlled Phase 2 study for the treat...

Pharmacyclics, Inc. Rights Offering Oversubscribed

...nouncement of today's offering, we have the capital to drive our programs forward, particularly PCI 32765, our novel BTK Inhibitor, and PCI 24783, our factor VIIa Inhibitor, to several inflection points. We are committed to driving shareholder value and look forward to updating you on our progress as we con...

Micromet Closes $80.5 Million Public Offering of Common Stock

...nical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, ...

Oncothyreon appoints Diana Hausman as Vice President of Clinical Development

...rug development will be very important as we prepare to move both PX-866, our inhibitor of PI-3 kinase, and PX-478, our inhibitor of hypoxia inducible factor 1-alpha, into Phase 2 trials. We are delighted to have her join our team." "I am very pleased to join Oncothyreon at this particular time in the dev...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... acute GI GVHD occurs in approximately 60 percent of related donor and 70 percent of unrelated donor allogeneic transplantation patients and is a risk factor for development of cGVHD. DOR has previously run two randomized, double-blind, placebo-controlled clinical trials in acute GI GVHD with orB...

OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.

...orward to becoming part of OmniComm," said Simon Kemp, Logos Technology Ltd.'s Managing Director. "OmniComm's team of industry professionals was a key factor in our decision making process. We have worked closely with OmniComm in the past with several joint clients and see this as an opportunity to enhance...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...nical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, ...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

...taining a gene or DNA vector encoding for a growth factor or any therapeutic protein. The Gene Activated Ma...sustained production of micro quantities of growth factor proteins or other therapeutic proteins based on th...verall level of protein required. Growth factor Gene Portfolio Growth...

Micromet Announces Pricing of Public Offering of Common Stock

...nical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, ...

Caliper Life Sciences Reports Second Quarter 2009 Results

...of divestitures) of $31 million in the third quarter of 2008. Caliper cited continuing strong demand for LabChip and IVIS instruments as a key factor in establishing this guidance. Adjusted Results Caliper supplements its GAAP financial reporting with certain non-GAAP financial measu...

Micromet Announces Public Offering of Common Stock

...nical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, ...

Breaking barriers with nanoscale lasers

...be the smallest a laser could be made for optical communications. In an optically denser medium such as a semiconductor, this limit is reduced by a factor of the index of refraction (expressed mathematically as ~3.0) of a semiconductor in this case to about 250 nanometers. The limit is sometimes call...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

...nd treat heart failure and cardiovascular diseases announced today that the US FDA cleared a phase I clinical trial for MyoCell SDF-1 (Stromal Derived factor - 1) to treat congestive heart failure. The REGEN trial will enroll 15 patients in a multicenter, randomized, dose escalation study to assess the saf...

PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2

... is designed to selectively block tumor-related vascular endothelial growth factor (VEGF). With its novel mechanism of action, PTC299 has the potential to me...und that inhibits the production of the protein vascular endothelial growth factor (VEGF) in tumors. PTC discovered PTC299 through PTC's proprietary GEMS (Ge...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...nical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, ...

FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business

...erently than the seasonal flu, which is typically absent during the summer months in the Northern Hemisphere," Dr. Lieberman continued. "When you also factor in the rapid global spread of the virus, particularly the increasing number of cases in certain countries in the Southern Hemisphere, it appears incre...

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

...very technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activit...

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

...nti-VEGF monoclonal antibody, r84, which is the most advanced candidate in Peregrine's anti-VEGF antibody program, targets the cancer-promoting growth factor VEGF. Data presented at IBC's 5th Annual International Anti-Angiogenesis Conference in 2007 showed that r84 was as effective as Avastin(R) (bevacizum...

Looking Older Than You Are May Have Little to Do With Wrinkles

... What's the biggest aging factor and how is it addressed? International Sculptra trainer Dr. Rebecca Fitzgerald, known among her medical colleagues as the "Sculptra guru" he...